Open AccessP533: SINGLE‐CENTER PHASE 2 STUDY OF PD‐1 INHIBITOR COMBINED WITH DNA DEMETHYLATION AGENT + CAG REGIMEN IN PATIENTS WITH HIGH‐RISK ACUTE MYELOID LEUKEMIA: INTERIM ANALYSIS
Author(s) -
Gao X.N.,
Su Y.F.,
Jing Y.,
Wang J.,
Xu L.,
Zhang L.L.,
Wang A.,
Wang Y.Z.,
Li Y.F.,
Liu D.H.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000845020.97630.e7
Subject(s) - medicine , regimen , decitabine , cytarabine , myeloid leukemia , minimal residual disease , interim analysis , oncology , cyclophosphamide , leukemia , gastroenterology , chemotherapy , surgery , clinical trial , gene expression , dna methylation , gene , biochemistry , chemistry